The gelatinases and their inhibitors: the structure-activity relationships.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Experientia. Supplementum

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-3-0348-0364-9_3PMID 22642190
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy.

  2011cited by this paper
• Downregulation of matrix metalloproteinase-9 by melatonin during prevention of alcohol-induced liver injury in mice.

  2011cited by this paper
• Curcumin Alleviates Matrix Metalloproteinase-3 and -9 Activities during Eradication of Helicobacter pylori Infection in Cultured Cells and Mice

  2011cited by this paper
• Matrix metalloproteinases in health and disease: regulation by melatonin

  2011cited by this paper
• The impact of the extracellular matrix on inflammation

  2010cited by this paper
• Inhibition of tumor growth and induction of apoptosis in prostate cancer cell lines by overexpression of tissue inhibitor of matrix metalloproteinase-3

  2010cited by this paper
• Thrombin-dependent MMP-2 Activity Is Regulated by Heparan Sulfate*

  2010cited by this paper
• Matrix metalloproteinases: regulators of the tumor microenvironment.

  2010cited by this paper
• Melatonin protects against endometriosis via regulation of matrix metalloproteinase‐3 and an apoptotic pathway

  2010cited by this paper
• Melatonin promotes angiogenesis during protection and healing of indomethacin‐induced gastric ulcer: role of matrix metaloproteinase‐2

  2010cited by this paper
• Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain.

  2010cited by this paper
• Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9.

  2009cited by this paper
• A new redox-dependent mechanism of MMP-1 activity control comprising reduced low-molecular-weight thiols and oxidizing radicals

  2009cited by this paper
• 17β-Estradiol inhibits matrix metalloproteinase-2 transcription via MAP kinase in fibroblasts

  2009cited by this paper
• Autocrine actions of matrix metalloproteinase (MMP)-2 counter the effects of MMP-9 to promote survival and prevent terminal differentiation of cultured human keratinocytes.

  2008cited by this paper
• The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2

  2008cited by this paper
• Proteolytic activation of matrix metalloproteinase-9 in skin wound healing is inhibited by alpha-1-antichymotrypsin.

  2008cited by this paper
• Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors.

  2008cited by this paper
• TGF-beta1 induced MMP-9 expression in HNSCC cell lines via Smad/MLCK pathway.

  2008cited by this paper
• Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity.

  2007cited by this paper
• The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases

  2007cited by this paper
• Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer.

  2007cited by this paper
• Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases

  2007cited by this paper
• Matrix metalloproteinases and the regulation of tissue remodelling

  2007cited by this paper
• Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins

  2007cited by this paper
• Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis

  2007cited by this paper
• Matrix metalloproteinase‐9 activity and expression is reduced by melatonin during prevention of ethanol‐induced gastric ulcer in mice

  2007cited by this paper
• The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors*

  2006cited by this paper
• Tissue Inhibitors of Metalloproteinases (TIMPs): Their Biological Functions and Involvement in Oral Disease

  2006cited by this paper
• Structure and function of matrix metalloproteinases and TIMPs.

  2006influential reference
• Human Mast Cell-Derived Gelatinase B (Matrix Metalloproteinase-9) Is Regulated by Inflammatory Cytokines: Role in Cell Migration1

  2006cited by this paper
• What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?

  2006cited by this paper
• Cag Pathogenicity Island-independent Up-regulation of Matrix Metalloproteinases-9 and -2 Secretion and Expression in Mice by Helicobacter pylori Infection*

  2006cited by this paper
• Hydrogen peroxide-mediated downregulation of matrix metalloprotease-2 in indomethacin-induced acute gastric ulceration is blocked by melatonin and other antioxidants.

  2006cited by this paper
• Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent

  2005cited by this paper
• Metalloproteinase inhibitor TIMP‐1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration

  2005cited by this paper
• Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β

  2005cited by this paper
• Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity.

  2005cited by this paper
• Gelatinase-mediated migration and invasion of cancer cells.

  2005cited by this paper
• A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women

  2005cited by this paper
• Quantification of Tissue Inhibitor of Metalloproteinases 2 in Plasma from Healthy Donors and Cancer Patients

  2005cited by this paper
• MATRIX METALLOPROTEINASE-2 (MMP-2) AND MMP-9 IN PULMONARY PATHOLOGY

  2005cited by this paper
• TIMP-2: an endogenous inhibitor of angiogenesis.

  2005cited by this paper
• Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice.

  2005cited by this paper
• Measurement of the Uncomplexed Fraction of Tissue Inhibitor of Metalloproteinases-1 in the Prognostic Evaluation of Primary Breast Cancer Patients*

  2005cited by this paper
• Curcumin Regulates Expression and Activity of Matrix Metalloproteinases 9 and 2 during Prevention and Healing of Indomethacin-induced Gastric Ulcer*

  2005cited by this paper
• A convenient synthesis of a selective gelatinase inhibitor as an antimetastatic agent.

  2004cited by this paper
• Liver regeneration: from myth to mechanism

  2004cited by this paper
• Mitochondrial redox control of matrix metalloproteinases.

  2004cited by this paper
• TIMP3 checks inflammation

  2004cited by this paper
• Matrix Metalloproteinase-9 Is Required for Adequate Angiogenic Revascularization of Ischemic Tissues: Potential Role in Capillary Branching

  2004cited by this paper
• Sultam hydroxamates as novel matrix metalloproteinase inhibitors.

  2004cited by this paper
• Matrix metalloproteinases as modulators of inflammation and innate immunity

  2004influential reference
• Matrix Metalloproteinase-9 Deficiency Results in Enhanced Allergen-Induced Airway Inflammation1

  2004cited by this paper
• Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species.

  2004cited by this paper
• Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines

  2004cited by this paper
• Matrix metalloproteinases and vascular endothelium-mononuclear cell close encounters.

  2004cited by this paper
• Low Density Lipoprotein Receptor-related Protein Mediates Endocytic Clearance of Pro-MMP-2·TIMP-2 Complex through a Thrombospondin-independent Mechanism*

  2004cited by this paper
• Promoter variants in tissue inhibitor of metalloproteinase-3 (TIMP-3) protect against susceptibility in pigeon breeders’ disease

  2004cited by this paper
• The Low Density Lipoprotein Receptor-related Protein LRP Is Regulated by Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Proteolysis in Malignant Cells*

  2004cited by this paper
• Matrix metalloproteinase‐2 (MMP‐2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP‐ribose) polymerase (PARP) in vitro

  2004cited by this paper
• TIMPs as multifacial proteins.

  2004cited by this paper
• The TIMPs tango with MMPs and more in the central nervous system

  2004cited by this paper
• Overexpression of the tissue inhibitor of metalloproteinase-3 during Xenopus embryogenesis affects head and axial tissue formation

  2004cited by this paper
• Altered fracture repair in the absence of MMP9

  2003cited by this paper
• X-ray structures of binary and ternary enzyme-product-inhibitor complexes of matrix metalloproteinases.

  2003cited by this paper
• Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer

  2003cited by this paper
• TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism.

  2003cited by this paper
• Hypochlorous Acid Generated by Myeloperoxidase Modifies Adjacent Tryptophan and Glycine Residues in the Catalytic Domain of Matrix Metalloproteinase-7 (Matrilysin)

  2003cited by this paper
• The Extracellular Matrix and Cytokines Regulate Microglial Integrin Expression and Activation1

  2003cited by this paper
• Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue

  2003cited by this paper
• Structural modeling extends QSAR analysis of antibody-lysozyme interactions to 3D-QSAR.

  2003cited by this paper
• Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium.

  2003cited by this paper
• Matrix metalloproteinases: a therapeutic target in cardiovascular disease.

  2003cited by this paper
• Cyclic phosphinamides and phosphonamides, novel series of potent matrix metalloproteinase inhibitors with antitumour activity.

  2003cited by this paper
• Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases define the migratory characteristics of human monocyte‐derived dendritic cells

  2002cited by this paper
• Analysis of Gelatinases in Complex Biological Fluids and Tissue Extracts

  2002cited by this paper
• Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP-3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix.

  2002cited by this paper
• Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations

  2002cited by this paper
• Gelatinase B deficiency protects against endotoxin shock

  2002cited by this paper
• Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.

  2002cited by this paper
• Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2

  2002cited by this paper
• Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells.

  2002cited by this paper
• Expression of Sorsby's Fundus Dystrophy Mutations in Human Retinal Pigment Epithelial Cells Reduces Matrix Metalloproteinase Inhibition and May Promote Angiogenesis*

  2002cited by this paper
• Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor.

  2002cited by this paper
• Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency

  2002cited by this paper
• Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene.

  2002cited by this paper
• Monocyte-derived dendritic cells express and secrete matrix-degrading metalloproteinases and their inhibitors and are imbalanced in multiple sclerosis.

  2002cited by this paper
• Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A2 and 5-lipoxygenase catalyzed pathway

  2002cited by this paper
• Strategies for MMP inhibition in cancer: innovations for the post-trial era

  2002influential reference
• Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding

  2002cited by this paper
• Activation of Matrix Metalloproteinase-2 by Overexpression of Manganese Superoxide Dismutase in Human Breast Cancer MCF-7 Cells Involves Reactive Oxygen Species*

  2002cited by this paper
• Intracellular Action of Matrix Metalloproteinase-2 Accounts for Acute Myocardial Ischemia and Reperfusion Injury

  2002cited by this paper
• Matrix metalloproteinases: they're not just for matrix anymore!

  2001cited by this paper
• N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.

  2001cited by this paper
• The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.

  2001cited by this paper
• Heterocycle-based MMP inhibitors with P2' substituents.

  2001cited by this paper
• Substrate Hydrolysis by Matrix Metalloproteinase-9*

  2001cited by this paper
• The High Molecular Weight Urinary Matrix Metalloproteinase (MMP) Activity Is a Complex of Gelatinase B/MMP-9 and Neutrophil Gelatinase-associated Lipocalin (NGAL)

  2001cited by this paper
• Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase.

  2001cited by this paper

• Deciphering the oncogenic influence of Pasteurella multocida: Implications of matrix metalloproteinase activation

  2025cites this paper
• Influence of N-arylsulfonamido d-valine N-substituents on the selectivity and potency of matrix metalloproteinase inhibitors.

  2023cites this paper
• Thermal stability of human matrix metalloproteinases

  2020cites this paper
• Substrate-zymography: a still worthwhile method for gelatinases analysis in biological samples

  2015cites this paper
• Development of in-cell imaging assay systems for MMP-2 and MMP-9 based on trans-localizing molecular beacon proteins

  2015cites this paper
• Association of MMP7 −181A→G Promoter Polymorphism with Gastric Cancer Risk

  2015cites this paper
• Targeting of ECM molecules and their metabolizing enzymes and receptors for the treatment of CNS diseases.

  2014cites this paper
• Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration.

  2014cites this paper
• Metalloproteinases and metalloproteinase inhibitors in age-related diseases.

  2014influential citation
• Matrix Metalloproteinases in Ischemia–Reperfusion Injury in Brain: Antioxidants as Rescuer

  2014cites this paper
• Expression of matrix metalloproteinases 9 and 12 in actinic cheilitis.

  2013cites this paper
• Des lapins watanabe au syndrome hyper IgE humain : caractérisation précoce de l'athérosclérose utilisant une probe optique ciblant l'integrin aVb3

  2012cites this paper
• Bioinformatics and expression analyses of the Ixodes scapularis tick cystatin family

  2012cites this paper